NURS 6521N Exam 1 V1 | NURS 6521N
Advanced Pharmacology | Actual Q&A
with Rationale (NURS6521N Exam 1) |
Walden University
1. When considering the pharmacokinetics in a neonatal patient, which factor most
significantly increases the risk of toxicity from highly protein-bound drugs?
A. Increased glomerular filtration rate
B. Reduced plasma protein levels
C. Enhanced hepatic enzyme activity
D. Decreased gastric pH
Answer: B
Rationale: Neonates have lower concentrations of serum albumin and other plasma
proteins compared to adults. This physiological difference leads to a higher percentage of
free, active drug circulating in the bloodstream. Consequently, the risk of drug-related
toxicity is significantly elevated for medications that are normally highly protein-bound.
2. A patient is prescribed an oral medication that undergoes extensive first-pass metabolism.
What is the clinical implication of this process?
A. The drug will have a rapid onset of action
B. The drug will bypass the liver via the portal vein
,C. The drug must be administered in lower doses than the IV route
D. A significant portion of the drug is inactivated by the liver before reaching systemic
circulation
Answer: D
Rationale: First-pass metabolism occurs when a drug is absorbed from the gastrointestinal
tract and enters the portal circulation. The liver then metabolizes the drug before it ever
reaches the systemic arterial blood. This process often necessitates higher oral doses
compared to parenteral doses to achieve a therapeutic effect.
3. Which FDA pregnancy category is assigned to drugs where studies in animals or humans
have demonstrated fetal abnormalities and the risk clearly outweighs any possible benefit?
A. Category B
B. Category X
C. Category D
D. Category C
Answer: B
Rationale: Category X signifies that the drug is strictly contraindicated during pregnancy
due to proven fetal risks. These risks have been documented in either human or animal
clinical trials. For these medications, the potential danger to the fetus is deemed more
significant than any therapeutic advantage for the mother.
, 4. The Cytochrome P450 (CYP450) enzyme system is primarily responsible for which phase of
drug metabolism?
A. Phase II conjugation
B. Renal secretion
C. Biliary excretion
D. Phase I oxidation, reduction, or hydrolysis
Answer: D
Rationale: The CYP450 system is a large group of enzymes located primarily in the liver
that facilitate Phase I metabolism. These enzymes modify drug molecules through
oxidation, reduction, or hydrolysis to make them more polar. This transformation is a
critical step in preparing drugs for eventual excretion from the body.
5. A drug has a half-life of 4 hours. If a dose of 100 mg is administered, how much of the drug
will remain in the body after 12 hours?
A. 50 mg
B. 12.5 mg
C. 25 mg
D. 6.25 mg
Answer: B
Advanced Pharmacology | Actual Q&A
with Rationale (NURS6521N Exam 1) |
Walden University
1. When considering the pharmacokinetics in a neonatal patient, which factor most
significantly increases the risk of toxicity from highly protein-bound drugs?
A. Increased glomerular filtration rate
B. Reduced plasma protein levels
C. Enhanced hepatic enzyme activity
D. Decreased gastric pH
Answer: B
Rationale: Neonates have lower concentrations of serum albumin and other plasma
proteins compared to adults. This physiological difference leads to a higher percentage of
free, active drug circulating in the bloodstream. Consequently, the risk of drug-related
toxicity is significantly elevated for medications that are normally highly protein-bound.
2. A patient is prescribed an oral medication that undergoes extensive first-pass metabolism.
What is the clinical implication of this process?
A. The drug will have a rapid onset of action
B. The drug will bypass the liver via the portal vein
,C. The drug must be administered in lower doses than the IV route
D. A significant portion of the drug is inactivated by the liver before reaching systemic
circulation
Answer: D
Rationale: First-pass metabolism occurs when a drug is absorbed from the gastrointestinal
tract and enters the portal circulation. The liver then metabolizes the drug before it ever
reaches the systemic arterial blood. This process often necessitates higher oral doses
compared to parenteral doses to achieve a therapeutic effect.
3. Which FDA pregnancy category is assigned to drugs where studies in animals or humans
have demonstrated fetal abnormalities and the risk clearly outweighs any possible benefit?
A. Category B
B. Category X
C. Category D
D. Category C
Answer: B
Rationale: Category X signifies that the drug is strictly contraindicated during pregnancy
due to proven fetal risks. These risks have been documented in either human or animal
clinical trials. For these medications, the potential danger to the fetus is deemed more
significant than any therapeutic advantage for the mother.
, 4. The Cytochrome P450 (CYP450) enzyme system is primarily responsible for which phase of
drug metabolism?
A. Phase II conjugation
B. Renal secretion
C. Biliary excretion
D. Phase I oxidation, reduction, or hydrolysis
Answer: D
Rationale: The CYP450 system is a large group of enzymes located primarily in the liver
that facilitate Phase I metabolism. These enzymes modify drug molecules through
oxidation, reduction, or hydrolysis to make them more polar. This transformation is a
critical step in preparing drugs for eventual excretion from the body.
5. A drug has a half-life of 4 hours. If a dose of 100 mg is administered, how much of the drug
will remain in the body after 12 hours?
A. 50 mg
B. 12.5 mg
C. 25 mg
D. 6.25 mg
Answer: B
